The clinical-stage immuno-oncology company expects to dose the first patient in early 2022.
About 100 patients will be randomized to receive either SRF388 or a placebo in combination with atezolizumab and bevacizumab. Surface Oncology anticipates a futility analysis in early 2023 and final data in H1 2024, it said.
The company also said it has expanded its debt facility with K2 HealthVentures to $50 million and maintains a projected cash runway through 2023.
Price: 7.90, Change: 0.00, Percent Change:
|MiMedx Says Glass Lewis Recommends in Favor of Direc...|
|T2 Biosystems Says It Secured US Patent Covering Met...|
|TherapeuticsMD Gets FDA Approval for Supplemental Ne...|
|Deere Raises Fiscal 2022 Profit Outlook After Postin...|
|Covetrus Says it Gets Proposal From Clayton, Dubilie...|